Novo Nordisk A/S Stock Forecast for 2023 - 2025 - 2030

Updated on 09/25/2023

Stock Rating
10
Price Target
kr975.00
Consensus
Outperform
Upside
0.78%
Analysts
16
Stock Rating
10
Upside
0.78%
Analysts
16
Price Target
kr975.00

Novo Nordisk A/S Stock Forecast and Price Target

If the average price target of kr975.00 set by sixteen distinguished experts for Novo Nordisk A/S over the past few weeks is reached this year, there would be a potential upside of approximately 0.78% from the last closing price in January, 2023. This potential increase is based on a high estimate of kr1200.00 and a low estimate of kr540.00. If you're thinking of investing in NOVO B stock, it's critical to check out its competitors as well.

kr975.00

0.78% Upside

Outperform
Outperform

Novo Nordisk A/S Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Novo Nordisk A/S's Price has seen an increase, rising from kr376.90 to kr477.23. This represents a growth of 26.62%. For the next year, 0 analysts project Novo Nordisk A/S's Fair Value to drop by 11.79%, reaching kr420.96. By 2030, professionals believe that Novo Nordisk A/S's Fair Value will decrease by 10.68%, reaching kr426.28 – a concerning trend for the company.

2022 Fair Value Forecast
kr420.96
2023 Fair Value Forecast
kr408.56
2024 Fair Value Forecast
kr412.98
2025 Fair Value Forecast
kr434.10
2026 Fair Value Forecast
kr429.92
2027 Fair Value Forecast
kr422.81
2028 Fair Value Forecast
kr419.70
2029 Fair Value Forecast
kr424.44
2030 Fair Value Forecast
kr426.28
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 10
$160.26 $179.95 12.63%
ROG Stock Forecast Roche Holding Outperform 5
CHF293.60 CHF384.23 24.32%
PFE Stock Forecast Pfizer Inc Outperform 3
$32.98 $44.13 59.64%
MRK Stock Forecast Merck Outperform 5
$105.84 $99.57 11.49%
AZN Stock Forecast AstraZeneca PLC Buy 8
£11.14k £153.20 -98.60%

Novo Nordisk A/S Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Novo Nordisk A/S's Revenue has seen an increase, rising from kr122.02B to kr140.80B. This represents a growth of 15.39%. For the next year, 0 analysts project Novo Nordisk A/S's Revenue to drop by 7.85%, reaching kr129.74B. By 2030, professionals believe that Novo Nordisk A/S's Revenue will decrease by 7.29%, reaching kr130.53B – a concerning trend for the company.

2022 Rev Forecast
kr129.74B
2023 Rev Forecast
kr127.49B
2024 Rev Forecast
kr127.68B
2025 Rev Forecast
kr131.99B
2026 Rev Forecast
kr131.26B
2027 Rev Forecast
kr130.01B
2028 Rev Forecast
kr129.25B
2029 Rev Forecast
kr130.16B
2030 Rev Forecast
kr130.53B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
NOVN Stock Forecast Novartis Hold 10
CHF85.77 CHF103.75 9.89%
ABT Stock Forecast Abbott Laboratories Outperform 10
$97.47 $124.05 28.24%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$59.16 $80.99 40.30%

Novo Nordisk A/S Dividend per Share Forecast for 2023 - 2025 - 2030

Novo Nordisk A/S's Dividend per Share has seen growth In the last two years, going from kr8.35 to kr10.40 – a gain of 24.55% According to 0 prominent analysts, Novo Nordisk A/S's Dividend per Share will fall by 11.08% in the next year, reaching kr9.25. By 2030, professionals believe that Novo Nordisk A/S's Dividend per Share will decrease by 10.07%, reaching kr9.35 – a concerning trend for the company.

2022 DPS Forecast
kr9.25
2023 DPS Forecast
kr8.99
2024 DPS Forecast
kr9.08
2025 DPS Forecast
kr9.51
2026 DPS Forecast
kr9.43
2027 DPS Forecast
kr9.28
2028 DPS Forecast
kr9.22
2029 DPS Forecast
kr9.31
2030 DPS Forecast
kr9.35
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
SAN Stock Forecast Sanofi Outperform 10
91.12€ 108.44€ 20.72%
AMGN Stock Forecast Amgen Inc Hold 7
$266.86 $268.00 4.17%
MDT Stock Forecast Medtronic Outperform 11
$79.97 $90.05 7.54%

Novo Nordisk A/S Free Cash Flow Forecast for 2023 - 2025 - 2030

Novo Nordisk A/S's Free Cash Flow has grown in the last two years, jumping from kr37.85B to kr48.67B – an increase of 28.57%. According to 0 major analysts, Novo Nordisk A/S's Free Cash Flow will fall by 11.74% in the next year, reaching kr42.95B. Professionals believe that By 2030, Novo Nordisk A/S's Free Cash Flow will fall to kr43.51B– a 10.60% decrease from its current value.

2022 FCF Forecast
kr42.95B
2023 FCF Forecast
kr41.47B
2024 FCF Forecast
kr42.20B
2025 FCF Forecast
kr44.33B
2026 FCF Forecast
kr43.89B
2027 FCF Forecast
kr43.09B
2028 FCF Forecast
kr42.81B
2029 FCF Forecast
kr43.31B
2030 FCF Forecast
kr43.51B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$74.85 $87.30 17.57%
CSL Stock Forecast CSL Buy 8
$254.88 $231.47 -11.31%
BSX Stock Forecast Boston Scientific Corp Outperform 15
$53.81 $52.51 -7.08%

Novo Nordisk A/S Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Net Income for Novo Nordisk A/S has grown by 22.61%, going from kr38.95B to kr47.76B. In the following year, 0 experts forecast Novo Nordisk A/S's Net Income will decrease by 10.37%, to kr42.81B. In 2030, professionals predict that Novo Nordisk A/S's Net Income will decrease by 9.46%, to kr43.24B.

2022 NI Forecast
kr42.81B
2023 NI Forecast
kr41.70B
2024 NI Forecast
kr42.04B
2025 NI Forecast
kr43.92B
2026 NI Forecast
kr43.57B
2027 NI Forecast
kr42.95B
2028 NI Forecast
kr42.66B
2029 NI Forecast
kr43.07B
2030 NI Forecast
kr43.24B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
GSK Stock Forecast GSK Outperform 16
£1.53k £16.95 -98.95%
SHW Stock Forecast Sherwin Williams Outperform 15
$256.21 $248.50 2.26%
BAYN Stock Forecast Bayer Outperform 7
46.32€ 74.54€ 63.00%

Novo Nordisk A/S EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Novo Nordisk A/S's EBITDA has increased by 12.86%, going from kr56.31B to kr63.55B. In the next year, 0 analysts estimate that Novo Nordisk A/S's EBITDA will decrease by 6.51%, reaching kr59.42B. According to professional forecasts, in 2030, Novo Nordisk A/S's EBITDA will decrease by 6.07%, reaching kr59.69B.

2022 EBITDA Forecast
kr59.42B
2023 EBITDA Forecast
kr58.48B
2024 EBITDA Forecast
kr58.63B
2025 EBITDA Forecast
kr60.25B
2026 EBITDA Forecast
kr59.98B
2027 EBITDA Forecast
kr59.48B
2028 EBITDA Forecast
kr59.20B
2029 EBITDA Forecast
kr59.55B
2030 EBITDA Forecast
kr59.69B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥4.07k ¥0.00 35.30%
BIIB Stock Forecast Biogen Inc Outperform 11
$255.02 $322.44 27.44%
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 16
¥4.08k ¥0.00 7.84%

Novo Nordisk A/S EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Novo Nordisk A/S's EBIT has grown, increasing from kr52.48B to kr59.34B – an increase of 13.07%. According to 0 analysts, Novo Nordisk A/S's EBIT will fall by 6.69% in the next year, reaching kr55.37B. Professionals believe that By 2030, Novo Nordisk A/S's EBIT will fall to kr55.64B – a 6.24% decrease from its current value.

2022 EBIT Forecast
kr55.37B
2023 EBIT Forecast
kr54.51B
2024 EBIT Forecast
kr54.61B
2025 EBIT Forecast
kr56.17B
2026 EBIT Forecast
kr55.91B
2027 EBIT Forecast
kr55.44B
2028 EBIT Forecast
kr55.17B
2029 EBIT Forecast
kr55.50B
2030 EBIT Forecast
kr55.64B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
PPG Stock Forecast PPG Industries Inc Outperform 13
$132.05 $138.33 6.78%
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$170.77 $244.18 46.98%
HZNP Stock Forecast Horizon Therapeutics Public Buy 16
$113.00 $0.00 23.89%

Novo Nordisk A/S EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Novo Nordisk A/S's EPS has seen an increase, rising from kr16.38 to kr20.74. This represents a growth of 26.62%. For the next year, 0 analysts project Novo Nordisk A/S's EPS to drop by 11.79%, reaching kr18.29. By 2030, professionals believe that Novo Nordisk A/S's EPS will decrease by 10.68%, reaching kr18.53 – a concerning trend for the company.

2022 EPS Forecast
kr18.29
2023 EPS Forecast
kr17.76
2024 EPS Forecast
kr17.95
2025 EPS Forecast
kr18.87
2026 EPS Forecast
kr18.68
2027 EPS Forecast
kr18.38
2028 EPS Forecast
kr18.24
2029 EPS Forecast
kr18.45
2030 EPS Forecast
kr18.53
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
IPN Stock Forecast Ipsen Hold 17
102.20€ 110.44€ 5.68%
500124 Stock Forecast Dr. Reddy's Laboratories Outperform 18
Rp4.27k Rp5.47k 15.97%
GRF Stock Forecast Grifols Outperform 18
12.21€ 27.25€ 73.63%